Back to top
more

Agios Pharmaceuticals (AGIO)

(Delayed Data from NSDQ)

$33.99 USD

33.99
812,040

+0.09 (0.27%)

Updated Aug 26, 2026 04:00 PM ET

After-Market: $33.98 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (157 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in Store for Agios Pharma (AGIO) in Q2 Earnings?

by Zacks Equity Research

Encouraging performance of Agios' (AGIO) lead candidate Idhifa, which is under review in the U.S. for treatment of AML might drive the stock in Q2.

    Zacks Equity Research

    Is Celgene (CELG) Poised For a Beat This Earnings Season?

    by Zacks Equity Research

    Celgene Corporation (CELG) is likely to beat on earnings estimates when it reports results on July 27 on the back of growth in Revlimid driven by share gains in important markets.

      Zacks Equity Research

      Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China

      by Zacks Equity Research

      Celgene Corporation (CELG) recently entered into a strategic collaboration with China based-BeiGene, Ltd. (BGNE).

        Zacks Equity Research

        Agios/Celgene's Leukemia Candidate Positive in Phase I/II

        by Zacks Equity Research

        Agios Pharmaceuticals, Inc. (AGIO) has announced a positive efficacy and safety data from the ongoing phase I/II study on experimental candidate IDHIFA (enasidenib) at an oral session at the European Hematology Association (EHA).

          Zacks Equity Research

          Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial

          by Zacks Equity Research

          Celgene Corporation (CELG) announced results from the phase II trial, SLE-001 which evaluated lupus candidate, CC-220, at the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid.

            Zacks Equity Research

            Agios (AGIO) Up 2.6% Since Earnings Report: Can It Continue?

            by Zacks Equity Research

            Agios (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Zacks Equity Research

              Celgene and Agios Announce Data on Idhifa for Leukemia

              by Zacks Equity Research

              Celgene Corporation (CELG) and Agios Pharmaceuticals, Inc. (AGIO) announced new efficacy and safety data on experimental candidate Idhifa (enasidenib).

                Zacks Equity Research

                Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review

                by Zacks Equity Research

                Jazz Pharmaceuticals plc (JAZZ) announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA.

                  Zacks Equity Research

                  Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus

                  by Zacks Equity Research

                  Agios Pharmaceuticals, Inc. (AGIO) posted first-quarter 2017 loss of $1.56 per share, narrower than the Zacks Consensus Estimate of a loss of $1.79 but wider than the year-ago loss of 61 cents.

                    Zacks Equity Research

                    Agios (AGIO) Q1 Loss Narrower than Expected; Sales Down Y/Y

                    by Zacks Equity Research

                    Agios posted narrower-than-expected loss in the first quarter of 2017. Our consensus called for a loss of $1.79 per share, and the company reported a loss of $1.56.